Practical Management of CD30 +Lymphoproliferative Disorders

Feb 12, 2018 by in Dermatology Comments Off on Practical Management of CD30 +Lymphoproliferative Disorders

Primary cutaneous CD30 + lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic…

read more

Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma

Feb 12, 2018 by in Dermatology Comments Off on Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma

Traditional chemotherapies, interleukins, phosphorylase inhibitors, and proteasome inhibitors are important therapies available to patients with cutaneous T-cell lymphoma (CTCL). Traditional chemotherapies, both in combination and as single agents, are commonly…

read more

Monoclonal Antibodies

Feb 12, 2018 by in Dermatology Comments Off on Monoclonal Antibodies

Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic…

read more

Methotrexate and Pralatrexate

Feb 12, 2018 by in Dermatology Comments Off on Methotrexate and Pralatrexate

This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides, Sézary syndrome, and CD30+ lymphoproliferative disorders. Although these folate antagonists…

read more
Get Clinical Tree app for offline access